The effect of subpectineal obturator nerve block on opioid consumption and pain after hip arthroscopy

Phase 1

Conditions: Postoperative pain after hip arthroscopy
MedDRA version: 21.0Level: LLTClassification code 10080604Term: Hip arthroscopySystem Organ Class: 100000004848
Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]

Registration Number: EUCTR2021-006575-42-DK

Lead Sponsor: Aarhus University Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 40

Inclusion Criteria

• Set for elective primary hip arthroscopy by one single orthopedic surgeon
• Planned generel anesthesia with propofol and remifentanil
• ASA I-III
• Patient = 18 years
• Informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 37
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 3

Exclusion Criteria

• Inability to cooperate
• Unable to speak and/or understand danish or other types of communication problems
• Allergy to local analgesics in the study (Marcain + adrenaline)
• Lack of tolerance of both Morphine and Oxycodone
• Chronic pain with daily opioid consumption (dosed > x 1 day)
• Chronic pain treated with gabapentin, pregabalin, tricyclic antidepressants, opioid antagonists or SNRI
• Treatment with antipsychotics
• Known abuse of alcohol, drugs or medicine
• Previous hip surgery on the planned side for the this hip arthroscopy
• Previous participation in this study
• Pregnancy

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: The purpose of the trial is to asses the analgesic effect of preoperatively placed active or placebo subpectineal obturator nerve block for elective primary hip arthroscopy. <br>The primary objective of the study is to investigate morphine consumption;Secondary Objective: The secondary goals are to investigate pain and morphine side effects. ;Primary end point(s): Cumulative opioidconsumption by PCA pump (patient controlled analgesia) in the first 180 min in PACU after primary hip arthroscopy for patients with active or placebo subpectineal obturator nerve block. ;Timepoint(s) of evaluation of this end point: 180 min after arrival to PAC

Secondary Outcome Measures